Meeting
2013 ASCO Annual Meeting
Activity and duration of chemotherapy (CT) in different biologic subtype (BS) in metastatic breast cancer (MBC) patients (P).
Authors
Claudia Bighin
Department of Medical Oncology, IRCCS AOU San Martino – IST, Genova, Italy
Claudia Bighin , Lucia Del Mastro , Beatrice Dozin , Sara Giraudi , Alessia Levaggi , Alessia D'Alonzo , Matteo Lambertini , Francesca Poggio , Giuseppina Iacono , Loredana Miglietta , Paolo Pronzato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1036)
DOI
10.1200/jco.2013.31.15_suppl.1036
Abstract #
1036
Poster Bd #
18C
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics.
First Author: Neelima Vidula
Poster
2023 ASCO Annual Meeting
Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829).
First Author: Joannie M. Ivory
Poster
2022 ASCO Annual Meeting
A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).
First Author: Se Hyun Kim
Poster
2021 ASCO Annual Meeting
Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.
First Author: Hans-Christian Kolberg